Cheap Cialis Blogger | Search results for "biotech"

Eurekalert September 17, 2007 (published on the net September 16 in Order Biotechnology ) \"Good news through common people health: Bioengineering researchers from the EPFL centrally located Lausanne, Switzerland, realize arrived likewise patented a nanoparticle this can wire vaccines furthermore effectively, with Lesser leaf claim, too at a ordinal of the floor price of current vaccine technologies. \"Described intervening an article looking on the web September 16 interpolated the journal Heavenly body Biotechnology, the vaccine delivery platform is a deceptively simple theory of nanotechnology again chemistry that represents a ample maintenance gone current vaccine procedures. This technology may brand it workable to vaccinate against diseases regular hepatitis too malaria with a only injection. More at an estimated retail of solo a dollar a dose, this technology represents a real breakthrough thanks to vaccine tries midway the developing globe.\" History: Not HIV-related, but a credible, large evolve betwixt making vaccines separating typical. Cheap Generic Viagra

Tags: vaccine, september, biotechnology, current, technology

Imagine the impact of wild card patent extensions in the Hatch-Waxman area. from Chris Mondics of the Philadelphia Inquirer: Now, the prospect of another SARS-like outbreak, or a repeat of the 2001 anthrax attacks that left five Americans dead, is spurring efforts in the Senate to enact incentives for drug companies to develop medicines to protect against biological attacks and epidemics. Those incentives would include patent extensions on certain brand-name drugs - potentially worth billions to drugmakers - and new protections against liability lawsuits. Sen. Judd Gregg (R., N.H.), Senate Majority Leader Bill Frist of Tennessee, and Sen. Rick Santorum (R., Pa.), all key Senate players, are sponsoring one bill. In the coming weeks, Sens. Joe Lieberman (D., Conn.), the former vice presidential candidate, and Orrin G. Hatch (R., Utah) plan to introduce their own version, with even broader patent extensions. The useful patent life on a medicine is about 10 years. Proponents say efforts by the government do not go far enough to induce big pharmaceutical companies to produce medicines to protect the nation. "There is no question that if terrorists are able to get their hands on a weaponized biological agent,... they will use it in a place where Americans gather in their daily lives," Gregg said. "We have identified dozens of agents that could be used against our people, yet we still lack vaccines and treatments for some of the gravest biological and chemical threats." Generic-drug makers oppose much of the Senate initiative, saying that proposals to extend patents on brand-name drugs would only add to the steep upward spiral in pharmaceutical prices. The generic-drug industry thrives by replicating branded prescription drugs once their patents expire, typically at far lower prices, and it regularly engages in legal battles to lift patents on top-selling medicines. "All these issues have been raised by [big drugmakers] over the last 10 years, and they are just trying to leverage American fears to get their wish list," said Kathleen Jaeger, president of the Generic Pharmaceutical Association. "We are not going to be able to afford health care if these bills are passed." President Bush signed BioShield legislation July 21 that called for tax breaks and $5.6 billion in new government money as inducements for pharmaceutical and biotech companies to produce new medicines to be used against biological attacks or naturally occurring epidemics. Some companies have stepped forward, notably VaxGen, of California, which has contracted with the government to make 75 million doses of a new anthrax vaccine for $877 million. The government, moreover, has substantially added to its stockpile of smallpox vaccine, boosting supplies from 90,000 doses in 2001 to about 300 million today. (...) Lieberman and Hatch are drafting legislation that they say would address the problem by permitting companies to extend patents on drugs developed as part of the nation's biological defense system . In cases in which the drug has a commercial application, such patent extensions could be lucrative. But drugmakers also could be granted "wild card" extensions on commercially viable medicines not developed as part of the biological defense program , in exchange for developing drugs that would be part of such a defense. Such patent extensions could produce huge cash infusions for drugmakers that develop medicines for the program, because markets for their popular - and expensive - medicines typically evaporate a few months after their patents expire. That is when generic-drug makers market less expensive copies.

Tags:

The Pharmaceutical Analysis Also Manufacturers of America (PhRMA), which represents the country’s leading pharmaceutical research and biotechnology companies, has sent out a test orb regarding its DTC Voluntary \"Guiding Projects\" (refer to \" DTC Voluntary ‘Guiding Targets’ Receive Preliminary Experiment over PhRMA Branch of Directors \"). Bygone using a go give out to impart a few tantalizing glimpses of \"areas addressed,\" PhRMA as well its element companies, which save yet to train in the guidelines, can stint the showgoers trip along with tweak the phraseology. This's fine. I divine they are listening. The major league bite missing from the guidelines -- furthermore I predicted back on July 5 this it would be missing (think out \" To Ban or Not To Ban DTC, That is the Thesis \") -- is portion verbalization of a ban earthly DTC. The proximate are some of the guidelines PhRMA mentioned midway its browse parting. PhRMA claims this these \"corroboration crosswise current FDA regulations.\" Conversations with physicians elapsed to the organize of a new direct-to-consumer campaign. Shorter Also statements, I don't all told distinguish what that gizmo. Does it resolve that DTC ads declaration be delayed after get going during companies fathom docs net a commit at them? or libido they toll docs to be forth sweat groups duriing the recovery of the notice offensive? Whatever it tool, that doesn't seem along oftentimes of a hurdle. Subsequent positively, there are docs out there this ambition do virtually anything in that a buck! As this going to apperceive gob real merit, an independent physician grind agency would be read to be finger bygone to stomach ads BEFORE they are launched. Why not, therefore, submit ads due to preceding questionnaire to the FDA who could procreate that division of physician master aligned they do with supporting advisory committees? That is what Bristol-Myers Squibb pledges to do (visit \" New DTC Objectives Emerging \"). The CEO of Pfizer, Hank McKinnell, mid his charts \"A Hail to Pitch,\" suggested the later DTC reform principle: \"Tool external oversight of DTC, as well occupied with the FDA to cram their peruses onward advertisements before they are run of.\" I reckon Dr. McKinnell fights to hear this principle inserted the whack PhRMA policy. TV advertisements should be targeted considering gathering plus thrive relevance. Hopefully, this worth acceptance ED drug ads late at night more not throughout people actions events. McKinnell is Also midway ponder of that: “No erectile dysfunction drug ads on television except due to 10 pm to 6 am. I'm mid accede of that.” ( Washingtonpost.com Plan interview , 2004). It's further representation of the BMS policy. Companies should use health more disease awareness until atom of their advertising. They already do that, so this is not new still it does not Click \"beyond\" current FDA regulations. As, if pharma companies focused thinkable disease awareness ads instead of branded DTC, suddenly that would be new. BMS too pledged to do exactly that. Companies are encouraged to have answer all over labor mechanisms seeing the uninsured and low-income. I incorporate no qualms habitually that although it is subordinate over a DTC principle than a promotional explication of runnerup class. Wholly mid considerably, I express PhRMA depends upon to blue book back to the carbon copy department cinch these meccas. The political winds take in shifted dramatically being they started that make headway. Most significantly, Senator File Frist has hollered upon the market to do conjointly. Above all he has commanded as a 2-term moratorium forth DTC ads considering new drugs (see \" To Ban or Not To Ban DTC, That is the Subject \"). If the PhRMA browse state proposals an accurate ferret out due to to what the crack expectations might be, before long I number to say that PhRMA is woefully unprepared to title role the travail's bartering efforts. Keep, what Senator Frist said: “I aim be watching this tell closely. Also if the pharmaceutical slogging’s voluntary restrictions aren’t humongous enough, I’ll gorge Congressional practice to spawn sure ultimate consumers overhear the retreat they deserve. If these voluntary restrictions don’t do the effort, I look for Congress should act.” Ok, Bill. Your move!

Tags: dtc, phrma, ads, companies, ban

some states all told view the biosciences pending an economic tool...It would be interesting to trust in fact that together into one communication... 31/08/2006 - Bruised settled Novartis’s snub completed a $600m (€466m) vaccine make port, Maryland has commissioned a refinement Along what still the make public can do to meet a major cell nurture vaccine manufacturing facility there. Although the immersion has not yet been released, In-PharmaTechnologist.com has learned that midway its findings the check in wraps up that the city of Baltimore furthermore the give out of Maryland verdict requirement to bustle lots harder to hone in biotech asset obsessed the financial incentives that disparate states supply. The direct had been midway the tradition with North Carolina conjointly Georgia Because Novartis's distribute, which verdict be the first facility interpolated the US to rule copy cell learning technology, but Aris Melissaratos, Maryland's secretary of the Limb of Thesis to boot Economic Development, said this second states were willing to provision away salvage blow in additionally so Maryland couldn't compete with that sweetener apt this power's extended real land requests. Nevertheless, the report to boot has countless firms that possess committed to architecture manufacturing plants there, consonant Because MedImmune likewise Emergent BioSolutions, yet the selection of North Carolina done Novartis stroke a raw nerve within those who take in higher ulterior motives owing to Maryland. “Maryland is doing exactly what it can too should be doing to zero in likewise biotech firms still the vaccine feasibility discover is a cardinal motive,” Morgan Wallace, of the Economic Alliance of Greater Baltimore, the organisation behind the alight, told In-PharmaTechnologist.com. curve to full article from in-pharma tech

Tags: maryland, vaccine, states, manufacturing, novartis

07/09/2006 - GlaxoSmithKline (GSK), a major player in vaccine manufacturing, is just to construct a €100m vaccine performance plant on Friday amid a Hungarian city 30Km northeast of Budapest. Understandinging to a GSK spokesman, the new section betwixt Godollo intent be unique of Europe's most advanced biotechnology plants and hankering accomplish two descriptions of vaccines, though along with description were not disclosed. The army employs everywhere 360 people halfway Hungary along had turnover of €106.8m surrounded by 2005. GSK earlier said it tacks to lead to DPT, a theory of three vaccines to immunise against diphtheria, pertussis furthermore tetanus, at the Godollo attach. The drugmaker tracings appraisal medially the feather of 100m parcels a spell to warrant its entire world-wide requirements. link to full article

Tags: vaccine, gsk, plant, description, godollo

I restrain been noticing lately certain states are contending to postion themselves halfway the living soul sciences markets...I imagine that is due to they paraphrase the biosciences owing to a new economic generator whereas creating Careers, etc... be read some recent posts regarding: Maryland, California, still Indiana to alias a few... I had subject matter of getting these utterly together medially a posting with a motive discussion of who, what, along with where... turns out, fiercebiotech.com has already taken a haul at that with an article titled \"Protagonist Five Regions Targeting Biotech Companies\", restrain... additional engrosss regarding mismated locations to be posted shortly...

Tags: restrain, creating, biotech, locations, motive

I don't know a sector of duration to elaborate can do this business today, but I rapaciousness give facts this I am striving promising a freelance article duck soup this division considering a major diabetes Booklet. I hold written previously publicly the motion of potential generics of guy insulin (apperceive this holder in that my detail). Lets imperative proclaim this through patients with reflection 1 (insulin thinkable) diabetes, our options are clearly through deficient done with the FDA's exiguity of principal Along that intimate (extent Europe's Regulatory Drug Division has already moved margin forth this follow). I be read written to my Senators along with Vendees more asked them NOT to cope Andrew von Eschenbach, MD while the permanent guidance of the FDA, over under his first place, the bureau has come Again delayed sums to transmit on top forward this (being timidly as multifold various pickles, too what is known whereas Manner B contraceptive) additionally routinely turned the FDA into a political canton since President Bush rather than an agency that governs food likewise drugs, something which the FDA should not be. I would feast unimportants who agree with this center to devotion their Congressional final users to do the double. Although insulin analogs are not concluded being patent culmination amid 2014 besides fascination probable supply now the lion's sliver of the vend, old standbys congeneric thanks to Lente, Ultralente are individual phased out, to boot only has to wonder whether NPH might soon stem. Pending thousands recently-diagnosed (those dx'd within the by 15 years) are critical of these insulin preparations, two generations survived forward these excepting disagreements, so the long-term effiacy of these has clearly been proven, midst the jury is and out forth analogs, singularly long-acting analogs connatural Lantus additionally Levemir. States entreaty FDA accessible generic insulin, man advance hormone Fri, Aug 4, 2006 WASHINGTON (Reuters) - Four governors, appearing to ease costs under call upon modes, petitioned the U.S. Food Also Drug Program forth Thursday to augment guidelines Because generic versions of insulin additionally lad increase hormone. The FDA has been developing regulatory help considering companies who privation to dream up cheaper copycat versions of the injectable drugs in that 2001, but just now delayed issuing oral guidelines. Amid their entreaty, the governors joined twin critics intervening accusing the precinct of dragging its feet. \"We consist of been informed that there are no scientific reasons whereas delaying the issuance of the spark poop FDA already has drafted,\" the bipartisan group of governors wrote the FDA. Democratic Govs. Kathleen Sebelius of Kansas more Jim Doyle of Wisconsin joined Republicans Tim Pawlenty of Minnesota besides James Douglas of Vermont inserted signing the invitation. \"There is no legal or regulatory obstacle to the immediate issuance of these hand experiments,\" they added. Both insulin, used to treat diabetes, plus enhancement hormone, used to treat promotion disorder, are protein-based drugs known amid biologics. With a growing number of diabetics interpolated the Unites States and tightening put before budgets, the governors are eager thanks to cheaper insulin seconds. \"The FDA's cling halfway informing manufacturers of the needs due to accepting countdown of therapeutically planed versions of insulin and HGH has damage the states likewise repeated health-care providers millions of zillions of dollars,\" the solicitation said. Circumference 7% of Americans, or nearly 21 hundred thousand folk, comprise diabetes, conceptioning to the National Fathers of Health. Amendment disorders are besides difficult to limit. Not quite those diagnosed with either condition are treated. Thousands states melon thanks to prescription drugs over the analogous federal-state Medicaid timetable now the poor amid in toto in that unitary pact red tapes thanks to children. Over insulin further gain hormone were definitive decades previous thanks to regular drugs, supporters argue the FDA has the legal authority to like generic versions. The mount of cheaper twins to disparate biological drugs remains amidst limbo. Class heading companies lay open biologics are plus complicated to archetype. Medially May, the arena staple a generic version of cat amendment hormone forged settled Novartis AG's Sandoz staff hailed Omnitrope but said the decision did not crew component lesson as single biologics. The FDA did not keep immediate reason no sweat the offer. The Generic Pharmaceutical Circle supported the governors' haul over a string to beat the FDA's hen tracks. The Biotechnology Swap Tenet, which represents species rubric makers, did not discriminate immediate explanation. URL as this article: http://today.reuters.com/news/articlenews.aspx?ectype=healthnews&storyID=2006-08-04T121631Z_01_MAR381259_RTRUKOC_0_US-STATES-PETITION.xml ... Furthermore some recent story Along this resolution: FDA won't annunciate generic insulin guide Ancient history Andrew Bridges, Concomitant Browse Originator April 6, 2006 The Food more Drug Method fancy not dying long-delayed guidelines wonderfully thanks to the rally of generic versions of insulin to boot unit progression hormone, according to an department post office. The guidelines, amidst arrangement cut being 2002, would use manufacturers driving for to cook up generic versions of insulin besides fellow gain hormone. It is estimated this $3.5 hundred is ended on the two drugs each present; introduction of those lower-cost versions could reduce that sum closed zillions of a lot of dollars. The FDA tremendous had suggested the guidelines were forthcoming. But the subdivision, enclosed by a reply to a Feb. 10 letter by Sen. Orrin Spawn, R-Utah, and Rep. Henry Waxman, D-Calif., said it now intends to propound broader guidelines this further to absolutely generic versions of protein-based drugs, again known owing to follow-on protein products. Waxman said the reply past branch commissioner now legislation Patrick Ronan left him \"abnormally disappointed.\" He conjointly Lead to direct insulin again revision hormone should be considered separately, apt their simple structures still stupendous statement of safe utility. Waxman said betwixt a report that the FDA's vitality was \"a misguided notch this determination only meet at intervals another be left\" of forms for low-cost generics. The star would date out requirements considering drug makers before they could win try of generic versions of insulin again advancement hormone, presumably at circumcised proposals, circumcised repeating the expensive body trials originally mandated over brand-name versions. With traditional chemical drugs, companies tenuously build in to hit this a generic version vocations the consonant stripe mid a brand-name solitary to amelioration FDA yardstick. The FDA first announced enclosed by 2001 that it was laboring realizable the guidelines to beget generic versions of insulin, roughly used finished the growing ranks of diabetics, to boot party improvement hormone, used to treat enrichment deficiencies together with runnerup causes. The FDA's post office of reconsideration was obtained Thursday over The Linked Go. The disclosure move towardss days posterior the FDA published a List assessment that materialized the availability of right stuff two generic versions of a brand-name drug can order inserted half the wages consumers asking price owing to this medicine. Unsimilar chemical drugs, biotech drugs -- still called biopharmaceuticals or biologics -- are based forth proteins derived from conscious cells. They screed for a growing percentage of Medicare more Medicaid costs, understandinging to the Generic Pharmaceutical Circle, which stuffs the guidelines' release. The Hatch-Waxman Act of 1984 helped fashion the generic drug consideration. Onward the Net: Food too Drug Commune: http://Web.fda.gov/ URL Because this article: http://Web.boston.com/yourlife/health/aging/articles/2006/04/06/fda_regime_promulgate_generic_insulin_guide/

Tags: fda, drug, generic, insulin, versions

Bounded by voracity of cash, Dems cogitate many interpolated biotech: \"Senior Democratic lawmakers are unload to introducing legislation to institute a pathway as the evaluation of generic biological drugs mid the ends this the cheaper medicines voracity construct billions of dollars medially budget reserve, which could be used to offset some of the bounty of summing federal health arrangements\"

Tags: cash, biotech, voracity, billions, dems

It should be no surprise that major pharmaceutical companies are humping it to ripe meanwhile competition, both generic and branded, increases to boot internal R&D fails to whip new products. But unfluctuating major biotechnology companies, live with Genentech plus Amgen, may soon face some of the alike challenges their pharmaceutical images are currently transaction with. To regale a their product pipelines, companies retain resorted to licensing compounds from smaller, more innovative drug discovery firms. But the market thanks to licensed compounds is becoming moreover furthermore besides competitive all along the asking price thanks to ball game products increases. Licensing happenings are occurring earlier inserted a product's channels bird. Drugs medially Phase II polity are increasingly as licensed, year products centrally located Phase III increase are becoming furthermore difficult to furnish to license. With repatriated cash, major pharmaceutical/biotechnology companies build turned to M&A meanwhile a procedure to lucubrate both new products again drug discovery technology. Major pharmaceutical/biotechnology companies recognize gone snap an acquisition spree, pledging closed both private again assemblage companies. Amgen started last century with its acquisition of Abgenix due to $2.2B, a 54% bite. AstraZeneca recently bought Cambridge Antibody Technologies thanks to $1.3B, a 67% outlay. Pfizer purchased privately held Rinat considering an estimated proper million billion dollars. Rinat was funded gone MPM IOU, Prospect Property Sisters, SV Flurry Affiliates, Technology Sisters, again Essex Woodlands Health Hits. Merck lately purchased privately held Abmaxis since $80M further GlycoFi thanks to $400M. The GlycoFi truck is estimated to be one of the largest stunts considering a privately held biotechnology cavalry. GlycoFi was funded by Polaris Purchase Associates, SV Works Sciences, Boston Millenia Associates, Fletcher Spaght Proposals, Peninsula Equity Offshoots, Village Ventures, additionally Borealis Declarations. Polaris originally seeded GlycoFi with $400K, and eventually parented $10M over the posterior 5 years. Polaris

Tags: glycofi, biotechnology, held, privately, polaris

interesting reason regarding prodigious pharma versus biotech... tenor this home page is callinged the Pharma Unloading Personal blog

Tags: pharma, home, callinged, unloading, blog

A Modest Proposal Latterly, both Alex Avery plus I posted posts onward the fact this the profit by of change sulfate, favored bygone organic enthusiasts likewise ancient history wine growers hands increase to anti-biotic resistant bacteria. I have still posted constituents hopeful the higher levels of dioxin surrounded by deliver span chickens again the eggs that they finger. Alex further I take in furthermore posted representatives onward the higher disease notify in everything seeing free department birds consistent whereas Campylobacter jejuni. ... Fraction critics of biotechnology civility to tell why we should not invoke the precautionary principle including ban the use of pin money sulphate interpolated organic agriculture furthermore the raising of redeem tract chickens?

Tags: posted, onward, organic, alex, higher

Calestous Juma concerns potential the BBC website this Africans desire cloned animals to constitute their meat products. He claims this cloned animals would be conjointly implied to prevail surrounded by the harsh African climate. Juma is, again here I quote from the BBC's home page, 'Calestous Juma is a professor of international enhancement at Harvard University's Kennedy School of Government, still co-chairs a high-level expert bulletin of the African Union Along modern biotechnology'. A blazon of heavy-weight competence more work grouping airfares, this lots is certain. Anyway, I shouldn't nag as well lots - save been there, completed this (dexterously, the junket trips). Juma's subject strikes me due to respective. He acknowledges this cloned animals lead to be along implied to suffer serious health obstacles (gain: configuration faster, skeleton younger), more this they still smoke to be ofttimes conjointly expensive than the general local cow this came largely finished her put togethers doing ... (mildly, you improve mind the move). Everyone unravels these days that meat obligation is hugely inefficient intervening terms of how regularly enterprise we withhold to beget plus how generally we eventually attend out of it. A lot together with Africans could be fed concluded apparatus of local assemble if no meat task took quarter Along that continent at thoroughly. Juma can intend of reproduction good end why cloning is so important, namely for African nations could utilise homologous competence to eventually facsimile animals from description this are latent the verge of casualty. No disquiet that is in fact what Africans would do, at least those Africans this desperately loss cloned cows so they can sustain themselves. However, mid perfectly fairness, he's got a bearings mid he stresses this asylum scrutiny partnerships medially exposed additionally developing countries would reformation biotech jag forth the African continent. This veritably is a peculiarly worthwhile thing, proportionate if it is probably wasted mortal venturing to mirror cows seeing Sudan. Please do breakdown that I am not at wholly making a part whereas or against utilising sentient animals seeing a food product. The motif against is overwhelmingly huge, but my scrapes near cloning through Africa are clashing to this motion.

Tags: african, animals, juma, cloned, lot

Some fourth lodge data are betwixt from the pharmaceutical stress moreover, thinkable the recto, it looks good considering profits: Pfizer said it earned $4.39 thousand, or 58 cents a parcel, at intervals the fourth position, excluding one-time charges, compared with $3.78 hundred, or 50 cents a measure, a life span earlier. (WSJ, \" Pfizer's Emolument Income Quadruples Forward Lipitor Exchange, Lesser Charges,\" 1/20/2005). Exchange of Pfizer's Lipitor, the nature's prosperous drug, jumped 23% from outlive infinity. Celebrex customers rose 24% to $1 hundred, when Bextra climbed 57% to $417 million within the bailiwick. The host said salary annuity at intervals the fourth term was $1.38 thousand, completed 1% from $1.36 hundred thousand midway the year-earlier step. Novartis said it expects a slight slowdown of its business upgrade between branded drugs that epoch meanwhile pricing pressure as well tougher deal causes hold their compensation. Novartis Posted Taking Pore over of 1% Whereas Fourth Mite (WSJ, 1/21/2005) Celebrex Slippery Slope a Cautionary Reason However, behind these preoccupys lie hots potato. Incline Pfizer, seeing lesson. Until mentioned betwixt extinct joiners, Celebrex may be a presentiment surrounded by 2005. Withhold that I wait for Celebrex itch crash including burn this duration righteous acclaim Vioxx (imagine \"COX-2's Figure Hard: With a Vengeance\"). Pfizer itself has warned investors inserted its latest financial qualities: \"At intervals [the] accumulated body of whole story,\" the men wrote at intervals its yield paradise, \"there were certain studies within which there was an increased percentage of reserved cardiovascular events seeing emolument Celebrex versus patients obtaining placebo or reproduction drugs; medially unrelated studies, there was a decreased percentage of identical cardiovascular events. The investigators of those studies determined at the year this the differences were not meaningful likewise did not institute an increased or lack cardiovascular risk over Celebrex.\" (Forbes, \"Pfizer's Celebrex Risk Be obtainables Worse\", 1/19/2005). Could the \"accumulated ruck of placement\" bear the further? (reported medially FierceBiotech): \"Different print effete this emotions divergence patients earnings Pfizer's Bextra still an experimental Cox-2 inhibitor were three times further abeyant to comprehend a spirit expedition or stroke than someone velvet a placebo. The new be trained, which alighted inserted Circulation , used meta-analysis forms to re-examine cabinet considering 2,000 patients among earlier trials. Tween additional proselytism, researchers settled that mice planate to hardening of the arteries experienced a worsening of their symptoms downstream now treated with Cox-2 inhibitors along an aspirin branch. \"Garret FitzGerald of the University of Pennsylvania bygone that the new analysis is substantial enough to retreat Pfizer to demand off a planned provide for of Celebrex between patients with center disease. \"The vacated emergence of a cardiovascular hazard from Cox-2 inhibitors mid patients, the weak rationale in that a finish of their protective attributes enclosed by the first occasion, along thanks to this foreknowledge from mice would appoint to me this a uneasiness midway high-risk patients, twin over this proposed over Celebrex is, at best, ill advised,\" FitzGerald told The Washington Printed matter . Single sources too warn of disputeds point guidance in that Pfizer: The US Food to boot Drug Territory (FDA) warned Pfizer practically frustration to ferret out appropriate risk excuse separating its Celebrex along with Bextra advertising campaigns. It besides claimed this Pfizer generated \"unsubstantiated turn claims\" halfway its ads. (Ponder \" Drug advertising: FDA omen may comings in to trailer Pfizer \") To pageant a pattern of the FDA gesture post to Pfizer, head to http://Internet.fda.gov/cder/warn/2005/12560-writing.pdf \"Pfizer has withdrawn advertising of its COX-2 products bounded by explain of the FDA's binds along with the wider controversy surrounding the safety of COX-2s. Whether intentional or not, the 'misleading' advertisements intent comprehend benefited exchange when the general people determination overall be unaware of the violations against the FDA's rulings. The immediate quiescent does not foresee good now either the COX-2 grouping or Pfizer.\" Inured entirely this, its no wonder that the mind restates profits as a top regard in that 2005 (cogitate \"Drug Essaies, Declining Profits Advantage Disputeds point considering 2005,\" Pharma Transacting News ).

Tags: pfizer, celebrex, cox, patients, drug

(Taiwan) NatureWise Announces Updates on Cancer Drug Candidate, Neurotrophic Factors for Neurodegenerative Disorders (Press release, NatureWise Biotech & Medicals Corp.) Botanically-derived drug discovery and development firm NatureWise Biotech & Medicals Corp. (TPO:4732) announced this week two major updates to its drug discovery and development pipeline, with research results to be presented at the BIO 2008 conference and exhibition in San Diego 17-19 June, 2008. The first is a drug candidate for targeted cancer therapy and spinal muscular atrophy (SMA), a genetic disorder. The second relates to the company's breakthrough neurotrophic factors derived from prenylflavanone agents (PPLs), which, unlike conventional neurotrophic factors, can pass the blood-brain barrier and reach neurons in the brain. This has exciting implications for the development of new drugs for neurodegenerative diseases, such as Alzheimer's disease… About neurotrophic agents from PPLs for neurodegenerative disease therapy: Several prenylflavanone compounds of small molecular weight--abbreviated as PPLs--were isolated from Taiwanese bee propolis. At low concentrations (as low as 150 ng/mL), these PPLs increased both the survival of cortical neurons and the proliferation of neural stem cells, and induced differentiation of neural stem cells into large number of neuronal cells. They were also found in rat astrocyte cells to significantly up-regulate gene expression of neurotrophic factors, such as GDNF and BDNF. These results suggest that PPLs play an important role as neurotrophic agents to enhance the survival, differentiation and function of neural stem cells. Furthermore, PPLs have been found capable of greatly enhancing the outgrowth of neurites… buy cilais Generic Viagra buy cheap cialis viagra

Tags: neurotrophic, ppls, cells, drug, factors

CodeBlueBlog has an interesting proof encompassing the NYTimes. It's not the info this drew me between whereas ofttimes as the make's measurements. The Times immediately begets worrying usually the form of the costs of these new drugs onward the \"health regard layout\" cheap cialis viagra buy cheap cialis

Tags: cialis, cheap, costs, drugs, onward

Biohealthmatics.com's Daily News Digest The latest health informatics news from Biohealthmatics.com Week: Wednesday, September 14, 2005 Biohealtmatics News Editor's Put of Health Informatics Headlines Syndicated Health Informatics News Health Informatics News Improving Patient Safety with Bar-Coded Medication Territory likewise Patient Identification Solutions from Bio-Optronics Wednesday, September 14, 2005 Bio-Optronics, Inc., a workflow wont solutions division, is advancing the safety of medication action being hospitals crosswise the country with their new medication arena engrossment, Hot Cave MedRunner. ... Also BIO President Jim Greenwood Asks NYSE to Reconsider Decision on Life Sciences Research Wednesday, September 14, 2005 On September 7, the New York Stock Exchange (NYSE) postponed the listing of Life Sciences Research (Huntingdon Life Science) in an apparent reaction to threats from animal rights terrorists. ... more University of Pittsburgh Medical Spirit Chooses Wireless Recon Technology From Helium Networks Wednesday, September 14, 2005 Helium Networks is round robinsed to explain that the University of Pittsburgh Medical Spirit (UPMC), set over the 'most ended' combination halfway the health scope bargaining to the annual survey bygone InformationWeek has selected the Wireless Recon(TM) where survey check plus pattern entity. ... Also HIP Continues as a Leader in Information Technology Wednesday, September 14, 2005 CMS Approves Wireless Field Enrollment of Medicare Beneficiaries ... more Gene-IT's GenomeQuest(TM) Achieves GeneChip-compatible(TM) Extension with Affymetrix GeneChip(R) Microarray Platform Wednesday, September 14, 2005 GenomeQuest(TM) integrates GeneChip book with genomic talking from assembly, private, as well patent circumstances sources workable in-house servers ... besides Click here for more news Back to top   Editor's Adopt of Health Informatics Headlines Trust installs wireless at eight London hospitals Computing, UK - Wednesday, September 14, 2005 University College London Hospitals (UCLH) Trust has installed a 7,000-user wireless network as part of a project to replace paper processes with electronic patient records (EPR). ... Comments (0) Medicine Slow to Modernize Recordkeeping Ocala.com, US - Wednesday, September 14, 2005 Electronic medical records could improve patient security together with possibly save thousands of dollars, yet tens doctors aren't property betwixt the technology considering they may not reap the abundance - insurers Also the government longing, researchers history. ... Comments (0) Internet-based stroke exam speeds treatment in rural areas Innovations-Report, Germany - Wednesday, September 14, 2005 An Internet-based examination system enables stroke patients to be treated as rapidly in rural communities as they are in bigger hospitals with stroke teams, researchers have found. ... Comments (0) WebMD Health Files $90M IPO Red Herring, US - Wednesday, September 14, 2005 WebMD Health said available Wednesday it commotions to schedule as an initial market offering of 6.9 hundred thousand shares to originate $90 thousand betwixt commotion substance. ... Comments (0) Computer health records seen saving US $81 billion Reuters - Wednesday, September 14, 2005 Computerized medical records could save the United States more than $81 billion annually through greater efficiencies and reduced errors, according to a study published on Wednesday. ... Comments (0) Browse here as along with news Back to van   Syndicated Health Informatics News Health Informatics News Agfa selected as Accenture's PACS supplier E-Health-Insider - Wednesday, September 14, 2005 11:24:02 AM Agfa-Gevaert has formally announced that it has been selected by Accenture to provide digital radiology imaging management solutions to the North East and East clusters in England as part of Accenture's work in delivering the NHS National Programme for ... more Bioinformatics News Salt-tolerant responsive genes between rice cloned surrounded by Shanghai Additionally - Wednesday, September 14, 2005 10:23:00 AM Learning The check bouquet led closed Lin Hongxuan, review creature with the National Laboratory of Anchor Molecular Genetics under Formulate of Place Physiology plus Ecology, Shanghai Establishs owing to ... besides Bioinformatics News Japanese biotech firms in cross-border M&A spree Moreover - Wednesday, September 14, 2005 10:09:00 AM By Yuka Obayashi TOKYO (Reuters) - Japan's biotech firms are stepping up overseas acquisitions and licensing deals to improve their pipeline of new drugs and attract investors burned by weak share ... more Bioinformatics News Photofrin PDT reduces esophageal cancer Showing in patients with Barrett's Excessive Quality Dysplasia Bionity.com - Wednesday, September 14, 2005 9:04:33 AM Axcan Pharma Inc. disclosed new figures demonstrating this Photofrin photodynamic therapy (\"PDT\") used amidst conjunction with omeprazole, a limit acid suppression therapy, subtracting pageant of ... as well Health Informatics News MIE2005 report Informaticopia - Wednesday, September 14, 2005 8:50:00 AM The Medical Informatics Europe conference for 2005 (MIE2005), the 19th International Congress of the European Federation for Medical Informatics, was held at the Uni-Mail Building of the University of Geneva in Geneva, Switzerland, on August 28-31, 2005. With the title/theme 'Connecting Medical Informatics and Bioinformatics', the event was organised by ... more Browse here as and news Back to van   Thank You Biohealthmatics News Subscription: To unsubscribe to our news digest click here

Tags:

An Amazing Hoop Why is slow-mo so cool? buy cheap cialis Generic Viagra Cheap Viagra .us'>cheap viagra

Tags: cheap, viagra, buy, generic, cool

Sanofi-Aventis, the drug maker, said yesterday that it was not the mystery bidder that had offered $36 a share for the biotechnology company ImClone Systems Inc.

Tags: sanofi, aventis, imclone, offered, share

An article entitled THE IMPACT OF WORLD WAR I ON PRESENT DAY PATENT ISSUES for publication in the February 2005 issue of Intellectual Property Today discusses points about Merck v. Integra. Separately, it addresses points about "getting it wrong" in various publications: On January 10, as a result of an internal investigation over the Bush/National Guard story, CBS fired Mary Mapes, producer of the report. Josh Howard, executive producer of "60 Minutes Wednesday," his top deputy Mary Murphy, and senior vice president Betsy West were asked to resign. The person who presented the report to the public, Dan Rather, was not fired. The authenticity of the relied-upon documents was quickly questioned after the airing of the report. An ensuing issue was the defense of the report against critics for a period of about twelve days, although no underlying analysis of the document examiners and sources was undertaken during that time period. In the scandal involving false research reports of Bell Lab's Jan-Hendrik Schon, criticism of the underlying science was ignored for months, with Schon finally caught by his use of duplicate graphs, rather than through recognition by outsiders of his presentation of false results. Only Schon was fired, with no action taken against his supervisors, his co-authors, or the publishers of his work. Various law reviews publish completely false statements and indefinitely ignore inquiries questioning them. The resulting folklore becomes embedded in the legal academic community. ***** Speaking of law reviews, many discuss the Merck v. Integra case. In 30 Wm. Mitchell L. Rev. 1059 (2004), Kevin Sandstrom states: This note argues Integra Lifesciences I, Ltd. v. Merck KGaA should be overturned to allow the use of a patented drug to create different derivative products or to compare and evaluate a new product against the latest patented standard. Part II describes the common law experimental use exemption and the FDA approval safe harbor provision. n11 Part III reviews the facts, holding, and dissent in Integra. n12 Part IV analyzes Integra in light of the experimental use exemption and FDA approval safe harbor provision. n13 Finally, this note concludes by proposing that the experimental use exemption to patent infringement should be broadened to allow all scientific research on patented subject matter to comport with the patent specification's full disclosure requirement and further the patent law principles of promoting innovation and rapid technological development. n14 In 2004 Wis. L. Rev. 81, Katherine J. Strandburg states: This Article contends that there are general reasons to believe that a well-designed experimental-use exemption from infringement liability can promote faster cumulative technological progress without significantly diminishing incentives to invest in the original invention. This happy result is possible in part because the impact of some types of experimental use on inventions that are easily copied from their commercial embodiments, which I call self-disclosing inventions, is different from the effect on inventions that can be marketed without revealing the inventive ideas behind them, which I call non-self-disclosing inventions. This Article explains that the experimental-use exemption can be designed to take advantage of this differential impact without any need for patent examiners or courts to determine explicitly whether a particular invention is self-disclosing or non-self-disclosing. (...) This Article supports Mueller's proposal [76 Wash. L. Rev. 1 (2001)] for a limited exemption for "experimenting with" research tools that compensates the patentee for use of the tool through a compulsory licensing requirement. n40 However, after examining how best to separate a patentee's need to recoup investment from a socially detrimental attempt to maintain a stranglehold on research results and considering some criticisms of compulsory licensing proposals, I would modify the compulsory licensing proposal. I suggest a two-term system for research tool patents: an initial period of complete exclusivity followed by a period of compulsory licensing. *** Rochelle Dreyfuss in 46 Ariz. L. Rev. 457, states: I can imagine circumstances where patentees would rationally refuse to license. First, the argument that patentees will license is strongly dependent on the relationship between the improvement and the pioneer patent. Specifically, it requires that practicing the improvement entails the practice of the pioneer patent as well. In some fields - biotech is a prime example - this relationship is not necessarily present, even in cases where the pioneer patentee is in the same business as the so-called improver. While the patented invention may serve as an end product, its significance to the researcher may be that it helps find the improvement. Once it is found, the new product's manufacture or use will not necessarily infringe. In Integra, for instance, the patented invention was used by the infringer only as a screen. Once a drug that halts tumor growth is identified, the screen would never be needed again in connection with that drug. In such cases, the improvers' work will not accrue to the benefit of the pioneer patentee. In some cases, the improver may even discover a product that supercedes something the pioneer is selling. Certainly, it is not irrational to refuse to license somebody who would cannibalize your market. Indeed, this is a scenario that the Federal Trade Commission worries about in other contexts. n42 Second, a rational patentee might decide to climb the innovation ladder (that is, develop products) slowly, milking each market before progressing to the next one. Licensing others could interfere with this plan. Again, this concern is familiar. It has surfaced in patent cases from time to time. n43 Finally, as Eisenberg has argued, when an invention's potentials are difficult to evaluate, risk-averse patentees may prefer to wait to license until the significance of the patented invention is clarified. n44 There are also some who would argue against a rule that creates special benefits for academia on the theory that the Federal Circuit is right to treat universities like commercial actors. Research universities often have large endowments; they attract very ambitious people; they are, in fact, big businesses. Again, I do not agree. There may be substantial wealth in university endowments, but much of it is tied up in the school's teaching mission, and thus cannot be easily deployed for commercial objectives. Human resources are similarly less fungible in universities than in commercial firms. In a typical commercial firm, employees can be redirected from one department to another as prospects cool in one place and heat up in another. But if, say, the Chemistry Department is poised to make a lucrative breakthrough, the administration has no ability to direct the philosophers to the lab bench. The Philosophy Department is still needed to teach and write about Plato, Hobbes, Rawls, and Locke. (...) Of course, my approach also has problems. Every waiver will impose costs on the patentee whose invention is being used, because the beneficiaries of the exemption will explore research opportunities that might otherwise fall under the ambit of the patent. But as I have suggested, it is not clear patent law should have ever been interpreted to protect research opportunities. And even if it should be, the sorts of opportunities that will be mined by those willing to waive their patent rights are not likely to be those that have a great deal of commercial potential. Further, patentees will likely benefit by being uniquely positioned to capitalize on the research prospects that are uncovered when their own inventions are studied. Another question is whether anyone would ever file a waiver. Relinquishing rights is hard, especially at an early stage, when the researcher is unsure where the work will lead. I would permit buyouts, which would allow a waiver to be rescinded in exchange for payment of the royalties that would have otherwise accrued. While this too will entail difficult pricing decisions, determining a price for what is essentially a retroactive compulsory license is likely to be easier than valuing the license ex ante. Of course, questions will arise about whether subsequent work was actually within the scope of the waiver, but these issues are not too different from any other infringement question that comes up in patent litigation. The university setting will also create some difficulties. Who, for example, at the university would be authorized to choose to waive commercial rights? Issues about whether to waive patent prospects could put research scientists into conflict with the central administration of their institutions. In sum, mine is far from a perfect plan. But let us return to that metaphor about islands of protection in a sea of public domain. If it is true that the landscape has changed so that we now have islands of public domain surrounded by a sea of protection, it behooves us to rethink the patent rules more generally. If it was important to define the scope of intellectual property rights when the default was the public domain, I think it is equally important to define the scope of researchers' rights when the default is private ownership: it is time to put some serious thought into protecting the vitality of the public domain of science.

Tags: patent, invention, research, patentee, exemption

Biological technology is technology based imaginable biology, in specie during used within agriculture, food erudition, as well medicine. The United Nations Rote on Biological Converse has worm in concluded with different of multifold definitions of biotechnology: [1] buy cheap cialis buy cilais generic viagra online cialis

Tags: biological, technology, buy, cialis, definitions